Vigilant Therapeutics
Keeping Hope Alive
by ensuring treatment options remain available to address the un-met medical needs of cancer patients.
Industry consolidation has resulted in the abandonment of orphan oncologics with smaller sales volumes, regulatory issues and/or complex manufacturing. Vigilant seeks to acquire a portfolio of these proprietary oncologics and ensure they remain available to address the un-met medical needs of cancer patients.
The company is currently evaluating licensing opportunities
by ensuring treatment options remain available to address the un-met medical needs of cancer patients.
Industry consolidation has resulted in the abandonment of orphan oncologics with smaller sales volumes, regulatory issues and/or complex manufacturing. Vigilant seeks to acquire a portfolio of these proprietary oncologics and ensure they remain available to address the un-met medical needs of cancer patients.
The company is currently evaluating licensing opportunities